With the implementation of advancing technologies in industry comes the parallel need for suitable upskilling of the workforce – but this doesn’t as yet always pan out, and in today’s pharmaphorum podcast COO of Enthought Mike Connell discusses the growing skills gap in R&D in life sciences and the 80/20 rule with web editor Nicole Raleigh, as well as the need for correct education of people and machines, both.

Chronic cough impacts up to 10% of the adult population and has a physical, psychological, and social impact on patients’ lives.

Farrell Simon, chief commercial officer at Trevi Therapeutics, joins web editor Nicole Raleigh on the pharmaphorum podcast to discuss prioritising patients in clinical and commercial development, with an especial focus on chronic cough.

There are currently no approved therapies in either the US or the UK for what is a highly disruptive affliction, accompanied by a wide range of complications, which causes a significant burden on patients, caregivers, and healthcare systems.

Also discussing Trevi’s own work in the field, in particular a potential treatment for idiopathic pulmonary fibrosis (IPF), the conversation explores how to work more closely and holistically with patients in clinical development. Integrating the patient voice is, as Simon says, critical in clinical trial design. After all, the patient is the utmost stakeholder.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ethan Drower, co-founder and CEO of Cite Medical Solutions, a company providing full Clinical Evaluation Report (CER) services and industry literature review for European Union Medical Device Regulation (or EU MDR) processes.

One of the things that makes patient engagement for pharma companies so challenging is that it's not something that can be added to one step of a process and then checked off the list. Real patient engagement needs to be integrated into processes every step of the way.

In today's podcast, brought to you by Reverba, Reverba CEO Cheryl Lubbert joins host Jonah Comstock to walk through the steps of the product lifestyle and explore the role of the patient at each of those stages: from preclinical through commercialisation and beyond.

Lubbert discusses the relationship between patient engagement, patient activation, patient centricity, and patient co-creation. She gives a wealth of examples from her experience as a long-time leader in the pharma industry to give context to the many ways to incorporate patients and their feedback into product discovery, clinical trials, product development, launch, and post-launch.

Finally, at the end of the podcast Lubbert gets into a few other hot-button issues including diversity and representation, as well as AI and how it will affect patient engagement. Tune in for interesting and actionable tips about patient engagement in pharma.

In today’s podcast, web editor Nicole Raleigh speaks with Carolyn Ward, director of clinical strategy at Particle Health Inc, a data transformation platform for healthcare, enabling organisations across the care continuum to turn medical records into actionable insights.

In today’s podcast, web editor Nicole Raleigh welcomes Dr Catherine Beech, CEO of Exonate, for a discussion on retinal vascular disease and a potential eye drop treatment for diabetic retinopathy and diabetic macular oedema, instead of invasive injections into the eye.

When it comes to life sciences manufacturing, there's nothing quite so daunting as a tech transfer - moving a product from development to commercialisation, or to a new facility or CDMO, presents many obstacles that have to be well thought out and planned. Delivering a tech transfer on schedule that stays below budget is no easy feat, but with the right best practices it can be done.

In today's podcast, brought to you by Lannett CDMO, Grant Brock, VP of operations at Lannett CDMO, and Frantz Maignan, Lannett CDMO's director of validation and tech services, join host Jonah Comstock for a deep dive into what challenges companies can encounter when it comes to tech transfers and some standout strategies for avoiding and surmounting those challenges.

The discussion includes the importance of thorough preparation and experimentation, good communication, and flexibility, and Brock and Maignan offer a few tips for choosing a manufacturing partner that can handle the unexpected bumps in the road that can crop up.

Tune in for a practical guide to an important and oft-overlooked aspect of pharma manufacturing.

We've recently passed the midpoint of 2024, so it's a good time to check in on trends – in this case, trends in the clinical trial space.

In today's podcast, brought to you by Advanced Clinical, host Jonah Comstock is joined by Jason Casarella, EVP of business development and marketing at Advanced Clinical and Caroline Redecker, chief strategy officer at Advanced Clinical, to discuss some of the findings in their recently released clinical trends report.

One of the biggest trends in the report is the rise of clinical trial site networks, and Casarella and Redecker drill down on why that’s happening and what it means for investigators. They also discuss how patient recruitment is changing in light of both changing technology and infrastructures, and new expectations about representation and diversity.

The conversation also veers into biotech investment trends and how those impact clinical trials, as well as the rise of AI and the various use cases being found for it in clinical research. Tune in for a wide-ranging snapshot into the evolving world of clinical research.

In this latest pharmaphorum podcast, web editor Nicole Raleigh speaks with Michael Kyle, chief medical officer at Currax Pharmaceuticals – a company working to advance a greater understanding of how to effectively treat obesity – about perceptions and options beyond the bounds of GLP-1s, including evolution of hypertension treatments.

The field of muscle stem cell research has been tangibly developing over the decades and in today’s pharmaphorum podcast wed editor Nicole Raleigh speaks with Dr Michael Rudnicki, co-founder and CSO of Satellos Biosciences, a company dedicated to developing novel therapeutics based on this science for those who live with Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases.